Ratings Sensorion

Equities

ALSEN

FR0012596468

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-07-12 am EDT			5-day change	1st Jan Change
0.696 ^EUR	+0.87%		+2.05%	+61.86%

Jul. 11	Certain Ordinary Shares of Sensorion SA are subject to a Lock-Up Agreement Ending on 11-JUL-2024.	CI
Jun. 27	Sensorion appoints new CFO	CF

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SENSORION	+61.86%	228M	-
MODERNA, INC.	+22.10%	46.55B	B-
LONZA GROUP AG	+46.45%	41.84B	A
IQVIA HOLDINGS INC.	-3.12%	40.84B	B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B	B
CELLTRION, INC.	-6.30%	28.27B	C
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B	B-
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B	B+
MEDPACE HOLDINGS, INC.	+44.52%	13.69B	C+
BIO-TECHNE CORPORATION	+0.19%	12.18B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes